Vastus Lateralis Fat Fraction is Associated with Functional Efficacy Endpoints in Patients with Duchenne Muscular Dystrophy Treated with Givinostat in EPIDYS
Craig M. McDonald, Francesco Bellanti, Sara Cazzaniga, Paolo Bettica, Ulrike Schara-Schmidt, Eugenio Mercuri, Michela Guglieri, Nuria Muelas Gómez, Krista Vandenborne
Efficacy of Givinostat by Age (6–7 and >7 years): A Post Hoc Analysis of EPIDYS
Chamindra G. Laverty, Federica Alessi, Nicoletta Coceani, Paolo Bettica, Dragana Vucinic
Characterizing Gastrointestinal Adverse Events of Interest From a Phase 3 Study of Givinostat in Patients With Duchenne Muscular Dystrophy
Erika L. Finanger, Liesbeth De Waele, Federica Alessi, Sara Cazzaniga, Paolo Bettica, John F. Brandsema
Characterizing Thrombocytopenia in Patients With Duchenne Muscular Dystrophy Treated With Givinostat: Results From the Phase 3 EPIDYS Trial
John F. Brandsema, Erika L. Finanger, Federica Alessi, Sara Cazzaniga, Paolo Bettica, Laura McAdam, Erik Niks
Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers
Han C. Phan, Eugenio Mercuri, Barry Byrne, Erik H Niks, Ulrike Schara-Schmidt, Tracy Willis, Thierry Le Tourneau, Odile Boespflug-Tanguy, Michela Guglieri, Nuria Muelas Gómez, David Gómez Andrés, Sergio César Díaz, John Bourke, Sara Cazzaniga
Cardiac Safety Data for Givinostat in Ambulant Patients with Duchenne Muscular Dystrophy: Results from EPIDYS Study
Han C. Phan, Eugenio Mercuri, Barry Byrne, Erik H Niks, Ulrike Schara-Schmidt, Tracy Willis, Thierry Le Tourneau, Odile Boespflug-Tanguy, Michela Guglieri, Nuria Muelas Gómez, David Gómez Andrés, Sergio César Díaz, John Bourke, Sara Cazzaniga